Benzimidazole Compounds for Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies for heart failure and diabetes lack effective methods to differentiate embryonic stem cells into functional cardiomyocytes and insulin-producing cells, leading to low yields and limited therapeutic efficacy.
Innovation Solution
Development of dihydropyridine-based, benzimidazole-based, phenothiazine-based, and tamoxifen-based compounds that promote stem cell differentiation into cardiomyocytes and insulin-producing cells by contacting embryonic stem cells with these compounds, facilitating the production of functional differentiated cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic stem cells are used for differentiation into cardiomyocytes, then the potential for replacing damaged heart tissue is improved, but the yield of functional cardiomyocytes is low
Solution Approach 1:
The patent employs small molecule compounds that alter biochemical parameters within stem cells to drive differentiation toward cardiomyocytes. These compounds modify cellular signaling pathways, gene expression profiles, and metabolic states to enhance cardiomyocyte yield while maintaining therapeutic quality
Solution Approach 2:
Small molecule compounds serve as intermediaries between the stem cell culture system and the differentiation outcome. These molecules mediate the transition from pluripotent stem cells to functional cardiomyocytes by modulating intracellular signaling pathways and transcriptional programs
2Reliability
If stem cell transplantation is performed to replace lost cardiomyocytes, then heart function restoration is improved, but transplanted cell survival is low
Solution Approach 1:
The patent applies differentiation-inducing compounds during in vitro culture to pre-establish functional characteristics and improve survival capacity before transplantation. This preliminary differentiation and conditioning enhances the resilience and engraftment potential of transplanted cells
Solution Approach 2:
The small molecule compounds induce stem cells to self-differentiate into cardiomyocytes with inherent survival advantages. The differentiated cells develop self-sustaining functional programs and resistance mechanisms that improve post-transplantation survival without requiring external support systems
3Reliability
If current stem cell differentiation methods are used, then research progress is made, but the complexity of differentiation protocols increases
Solution Approach 1:
The patent extracts and isolates specific small molecule compounds that can independently drive cardiomyocyte differentiation. By identifying discrete molecular entities with defined activities, the complex multi-factor differentiation protocols are simplified into more manageable and controllable regimens
Data Source
AI summary
Methods and small molecule compounds for stem cell differentiation are provided. One example of a class of compounds that may be used is represented by the compound having the structure IA or IB in the form of free base or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof:R1 is independently hydrogen or (C1-C6)alkyl; R2 is independently hydrogen, (C1-C6)alkyl, aryl, or heteroaryl; R2′ is independently hydrogen, (C1-C6)alkyl, CF3 or C2F5; R3 is independently (C1-C6)alkyl, aryl, 2-tetrahydrofurylmethyl, an aliphatic tertiary amine, or 4-methoxybenzyl; or R2 and R3 may be joined together to form a 5 or 6 member ring lactone; R4 is independently hydrogen, (C1-C6)alkyl, a 2- or 4-R5-substituted aromatic ring selected from a 4-R5-phenyl or a 2-R5-5-pyridyl, aryl, heteroaryl, aliphatic tertiary amine or halogen; and R5, R5′, R6, R6′, R7, R7′, are each independently hydrogen, (C1-C6)alkyl, aryl, optionally substituted phenyl, heteroaryl, a heterocyclic ring, an aliphatic tertiary amine, or halogen.